VERVE THERAPEUTICS INC's ticker is VERV and the CUSIP is 92539P101. A total of 122 filers reported holding VERVE THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.13 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,725,421 | -45.6% | 205,537 | -23.0% | 0.00% | 0.0% |
| Q2 2023 | $5,007,713 | +32.1% | 267,078 | +1.6% | 0.00% | 0.0% |
| Q1 2023 | $3,791,638 | -50.3% | 262,943 | -33.3% | 0.00% | -50.0% |
| Q4 2022 | $7,628,428 | -26.8% | 394,234 | +30.0% | 0.00% | 0.0% |
| Q3 2022 | $10,421,000 | +811.7% | 303,353 | +305.8% | 0.00% | – |
| Q2 2022 | $1,143,000 | -52.9% | 74,759 | -29.7% | 0.00% | -100.0% |
| Q1 2022 | $2,427,000 | +25.6% | 106,368 | +103.0% | 0.00% | – |
| Q4 2021 | $1,932,000 | -2.5% | 52,400 | +24.3% | 0.00% | – |
| Q3 2021 | $1,981,000 | -72.3% | 42,154 | -64.4% | 0.00% | -100.0% |
| Q2 2021 | $7,140,000 | – | 118,513 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARCH Venture Management, LLC | 2,008,809 | $26,636,807 | 17.30% |
| Alphabet Inc. | 10,549,086 | $139,880,880 | 8.98% |
| Casdin Capital, LLC | 2,954,710 | $39,179,455 | 4.34% |
| MPM BioImpact LLC | 857,940 | $11,376,284 | 3.04% |
| Saltoro Capital, LP | 66,500 | $881,790 | 0.79% |
| ARK Investment Management | 5,200,567 | $68,959,525 | 0.53% |
| Redmile Group, LLC | 809,777 | $10,737,643 | 0.51% |
| Ikarian Capital, LLC | 2,413 | $3,199,638 | 0.38% |
| Logos Global Management LP | 215,000 | $2,850,900 | 0.38% |
| Nikko Asset Management Americas, Inc. | 2,147,243 | $28,429,497 | 0.34% |